Scalper1 News
Shares of Biogen (BIIB) and Eli Lilly (LLY) were both moving as they reported data on their key drug candidates for Alzheimer’s disease Wednesday, while Wall Street debated the meaning of the results. Biogen’s aducanumab was the particular focus of attention. At the Alzheimer’s Association International Conference (AAIC), the company reported the effects of aducanumab on patients with mild or prodromal (i.e. even earlier than mild) Alzheimer’s Scalper1 News
Scalper1 News